Sulfasalazine is a well established disease-modifying anti-rheumatic drug commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. Sulfasalazine was generally well tolerated in clinical trials, the most frequently reported adverse effects being adverse gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. We are now reporting the first case of autoimmune thrombocytosis following sulfasalazine treatment.
Cantarini, L., Tinazzi, I., Biasi, D., Fioravanti, A., Galeazzi, M. (2007). Sulfasalazine-induced immune thrombocytopenia. POSTGRADUATE MEDICAL JOURNAL, 83(980), Article Number: e1 [10.1136/pgmj.2006.055194].
Sulfasalazine-induced immune thrombocytopenia.
CANTARINI, LUCA;GALEAZZI, MAURO
2007-01-01
Abstract
Sulfasalazine is a well established disease-modifying anti-rheumatic drug commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. Sulfasalazine was generally well tolerated in clinical trials, the most frequently reported adverse effects being adverse gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. We are now reporting the first case of autoimmune thrombocytosis following sulfasalazine treatment.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/6754
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo